How Par Drugs and Chemicals' abrupt pivot exposes overlooked risks of micro cap investing
05-Dec-2024•Vishal Goyal
AI-generated image
हिंदी में भी पढ़ें 
Register for free on Value Research now to enjoy the lifetime access
Register Now
Already have an account? Log In
Why is PPFAS's flexi-cap fund sitting on 20 per cent cash? Raunak Onkar explains.
6 min read•By Value Research Team
Year's hottest fund vs KISS fund: Which strategy delivers higher returns?
4 min read•By Ashish Menon and Abhishek Rana
New episodes every Friday
Experts and the thali of wisdom
You know how some restaurants proudly advertise thalis with dozens of dishes? Market experts are like that.
Other Episodes
The thinking investor's advantage
Just as AI writing tools can't replace clear thinking, investment apps can't substitute for real investment understanding
Speed limits for investors
Why going faster makes a big difference at first but becomes pointless - and dangerous - after a point
Playing the long game
The tectonic shifts shaping India's next decade of wealth creation
Spectacular wealth through simple investing
The power of patient investing and why doing nothing may be better than doing just anything
Denta Water and Infra Solutions IPO analysis
5 min read•By Shubham Dilawari
IT Q3 report card: How have the big four fared?
3 min read•By Abhinav Goel
Our rating system has guided millions of investors in the past 20 years.
Widely read:
